Adalimumab (HUMIRA): A Review
August 2003 | Volume 2 | Issue 4 | Original Article | 375 | Copyright © August 2003
Noah Scheinfeld, MD,JD
Adalimumab (HUMIRA™, Abbott Laboratories) is a new fully human TNF-? monoclonal antibody recently
approved for the treatment of rheumatoid arthritis and undergoing trials for use in treating other conditions,
including psoriasis and psoriatic arthritis. This article reviews its mechanisms of action, clinical trial results,
and related discussion.